Tezepelumab: Patient Selection and Place in Therapy in Severe Asthma

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2024 Apr 27

PMID 38676539

Authors

Francesco Menzella

Sara Munari

Lorenzo Corsi

Silvia Tonin

Walter Cestaro

Andrea Ballarin

Ariel Floriani

Cristina Dartora

Gianenrico Senna

Affiliations

Soon will be listed here.

Abstract

Asthma is a disease characterised by heterogeneous and multifaceted airway inflammation. Despite the availability of effective treatments, a substantial percentage of patients with the type 2 (T2)-high, but mainly the T2-low, phenotype complain of persistent symptoms, airflow limitation, and poor response to treatments. Currently available biologicals target T2 cytokines, but no monoclonal antibodies or other specific therapeutic options are available for non-T2 asthma. However, targeted therapy against alarmins is radically changing this perspective. The development of alarmin-targeted therapies, of which tezepelumab (TZP) is the first example, may offer broad action on inflammatory pathways as well as an enhanced therapeutic effect on epithelial dysfunction. In this regard, TZP demonstrated positive results not only in patients with severe T2 asthma but also those with non-allergic, non-eosinophilic disease. Therefore, it is necessary to identify clinical features of patients who can benefit from an upstream targeted therapy such as anti-thymic stromal lymphopoietin. The aims of this narrative review are to understand the role of alarmins in asthma pathogenesis and epithelial dysfunction, examine the rationale underlying the indication of TZP treatment in severe asthma, summarise the results of clinical studies, and recognise the specific characteristics of patients potentially eligible for TZP treatment.

References

Kato A, Favoreto Jr S, Avila P, Schleimer R . TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells. J Immunol. 2007; 179(2):1080-7. PMC: 2220044. DOI: 10.4049/jimmunol.179.2.1080. View

Bartemes K, Kita H . Dynamic role of epithelium-derived cytokines in asthma. Clin Immunol. 2012; 143(3):222-35. PMC: 3358585. DOI: 10.1016/j.clim.2012.03.001. View

Kozu Y, Gon Y, Maruoka S, Kazumichi K, Sekiyama A, Kishi H . Protocadherin-1 is a glucocorticoid-responsive critical regulator of airway epithelial barrier function. BMC Pulm Med. 2015; 15:80. PMC: 4521469. DOI: 10.1186/s12890-015-0078-z. View

Headley M, Zhou B, Shih W, Aye T, Comeau M, Ziegler S . TSLP conditions the lung immune environment for the generation of pathogenic innate and antigen-specific adaptive immune responses. J Immunol. 2009; 182(3):1641-7. PMC: 3195412. DOI: 10.4049/jimmunol.182.3.1641. View

Porsbjerg C, Sverrild A, Lloyd C, Menzies-Gow A, Bel E . Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020; 56(5). PMC: 7676874. DOI: 10.1183/13993003.00260-2020. View

Mitchell P, Salter B, Oliveria J, El-Gammal A, Tworek D, Smith S . IL-33 and Its Receptor ST2 after Inhaled Allergen Challenge in Allergic Asthmatics. Int Arch Allergy Immunol. 2018; 176(2):133-142. DOI: 10.1159/000488015. View

Kaur D, Gomez E, Doe C, Berair R, Woodman L, Saunders R . IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk. Allergy. 2015; 70(5):556-67. PMC: 4418379. DOI: 10.1111/all.12593. View

Pavord I, Bahmer T, Braido F, Cosio B, Humbert M, Idzko M . Severe T2-high asthma in the biologics era: European experts' opinion. Eur Respir Rev. 2019; 28(152). PMC: 9489011. DOI: 10.1183/16000617.0054-2019. View

Tang W, Smith S, Beaudin S, Dua B, Howie K, Gauvreau G . IL-25 and IL-25 receptor expression on eosinophils from subjects with allergic asthma. Int Arch Allergy Immunol. 2013; 163(1):5-10. DOI: 10.1159/000355331. View

10.

Corren J, Ziegler S . TSLP: from allergy to cancer. Nat Immunol. 2019; 20(12):1603-1609. DOI: 10.1038/s41590-019-0524-9. View

11.

Sverrild A, Hansen S, Hvidtfeldt M, Clausson C, Cozzolino O, Cerps S . The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Eur Respir J. 2021; 59(1). DOI: 10.1183/13993003.01296-2021. View

12.

Soumelis V, Reche P, Kanzler H, Yuan W, Edward G, Homey B . Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002; 3(7):673-80. DOI: 10.1038/ni805. View

13.

Lee H, Headley M, Loo Y, Berlin A, Gale Jr M, Debley J . Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection. J Allergy Clin Immunol. 2012; 130(5):1187-1196.e5. PMC: 4284103. DOI: 10.1016/j.jaci.2012.07.031. View

14.

Kuo C, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I . T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J. 2017; 49(2). DOI: 10.1183/13993003.02135-2016. View

15.

White S . Apoptosis and the airway epithelium. J Allergy (Cairo). 2011; 2011:948406. PMC: 3238401. DOI: 10.1155/2011/948406. View

16.

Andersson U, Tracey K . HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011; 29:139-62. PMC: 4536551. DOI: 10.1146/annurev-immunol-030409-101323. View

17.

Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y . IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest. 2007; 87(10):971-8. DOI: 10.1038/labinvest.3700663. View

18.

Cao L, Liu F, Liu Y, Liu T, Wu J, Zhao J . TSLP promotes asthmatic airway remodeling via p38-STAT3 signaling pathway in human lung fibroblast. Exp Lung Res. 2018; 44(6):288-301. DOI: 10.1080/01902148.2018.1536175. View

19.

Zhang S, Smartt H, Holgate S, Roche W . Growth factors secreted by bronchial epithelial cells control myofibroblast proliferation: an in vitro co-culture model of airway remodeling in asthma. Lab Invest. 1999; 79(4):395-405. View

20.

Kitajima M, Lee H, Nakayama T, Ziegler S . TSLP enhances the function of helper type 2 cells. Eur J Immunol. 2011; 41(7):1862-71. PMC: 3124605. DOI: 10.1002/eji.201041195. View